(TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) – Perimeter Medical
Imaging AI, Inc. (“Perimeter” or the “Company”) – a
commercial-stage medical technology company – today reported
leadership changes, including the appointment of Suzanne Foster as
Chair of its Board of Directors, effective immediately.
Jeremy Sobotta, Perimeter’s Chief Executive Officer stated,
“Suzanne is a global industry leader with more than 25 years of
healthcare experience. Her leadership and industry expertise will
be assets to all Perimeter stakeholders in this new capacity. She
is one of the longest-serving directors on our Board, and I look
forward to continuing to work closely with Suzanne in pursuit of
our mission to transform cancer surgery.” Mr. Sobotta continued,
“We are also grateful that Dr. Anthony Holler, Perimeter’s Chair
from 2019 to 2022, will continue to provide strategic advice and
serve as one of our directors moving forward.”
Ms. Suzanne Foster commented, “I am excited to take on the role
of Chair and support the advancement of Perimeter’s innovative
technology with the goal of improving patient outcomes and reducing
healthcare costs. When I was going through breast cancer treatment,
my surgeon used to say that she could cut out the cancer, but the
real miracles will happen when she can cut out the fear. My hope is
that surgeons who use Perimeter’s technology in the OR will reduce
the likelihood of a second surgery – but, importantly, also reduce
the fears and anxieties of their patients.”
Ms. Suzanne Foster is President of Beckman Coulter Life
Sciences. She is a global leader with more than 25 years of
experience in the healthcare industry. Previously, she held the
positions of President of Cardinal Health’s Health-at-Home and VP
General Manager Medtronic Advanced Energy. Earlier in her career,
she held various legal and compliance roles focused on health
systems and healthcare organizations. Ms. Foster holds a B.A. in
Communication from the University of New Hampshire, an M.Ed in
Psychology from Notre Dame College, a J.D. from Suffolk University
Law School, and a Master of Public Health in Law and Health Policy
from Harvard T.H. Chan School of Public Health.
In addition, the Company also announced that Chris Scott has
resigned as Chief Financial Officer (“CFO”), effective January 13,
2022. A formal search has been initiated, and the Company announced
that Russell Wagner will serve as Interim CFO until a new CFO is
appointed.
Mr. Russell Wagner is a CPA and an accomplished executive with a
track record of solid performance across all major finance,
accounting, and treasury functions in a healthcare setting. From
2003 until his retirement in 2020, Mr. Wagner was Executive Vice
President, Chief Financial Officer, and Treasurer at Holy Redeemer
Health System in Philadelphia, PA. Prior to assuming these CFO
duties, Mr. Wagner held VP-level roles of increasing responsibility
across the Finance function at Holy Redeemer Health from 1994 to
2003. Mr. Wagner began his career at the certified public
accounting firm of Heffler and Company in 1979, and was promoted to
partner in 1986, where his emphasis was healthcare auditing and
consulting until 1994. His clients included hospitals, nursing
homes, home health agencies, physician groups, and health insurance
companies. Mr. Wagner has a Bachelor of Business Administration
degree from Temple University in Philadelphia, PA.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical
technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level. The breakthrough-device-designated investigational Perimeter
B-Series OCT with ImgAssist AI represents our next-generation
artificial intelligence technology that is currently being
evaluated in a pivotal clinical trial, with support from a grant of
up to US$7.4 million awarded by the Cancer Prevention and Research
Institute of Texas. The company’s ticker symbol “PINK” is a
reference to the pink ribbons used during Breast Cancer Awareness
Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
“forward-looking information” within the meaning of applicable
Canadian securities legislation. In this news release, words such
as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management’s
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist and Perimeter’s business focus are forward-looking
information. Forward-looking statements should not be read as
guarantees of future performance or results, and will not
necessarily be accurate indications of whether, or the times at or
by which, any particular result will be achieved. No assurance can
be given that any events anticipated by the forward-looking
information will transpire or occur. Forward-looking information is
based on information available at the time and/or management’s
good-faith belief with respect to future events and are subject to
known or unknown risks, uncertainties, assumptions, and other
unpredictable factors, many of which are beyond Perimeter’s
control. Such forward-looking statements reflect Perimeter’s
current view with respect to future events, but are inherently
subject to significant medical, scientific, business, economic,
competitive, political, and social uncertainties and contingencies.
In making forward-looking statements, Perimeter may make various
material assumptions, including but not limited to (i) the accuracy
of Perimeter’s financial projections; (ii) obtaining positive
results from trials; (iii) obtaining necessary regulatory
approvals; and (iv) general business, market, and economic
conditions. Further risks, uncertainties and assumptions include,
but are not limited to, those applicable to Perimeter and described
in Perimeter’s Management Discussion and Analysis for the year
ended December 31, 2021, which is available on Perimeter’s SEDAR
profile at www.sedar.com, and could cause actual events or results
to differ materially from those projected in any forward-looking
statements. Perimeter does not intend, nor does Perimeter undertake
any obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230117005472/en/
Jeremy Sobotta Chief Executive Officer Perimeter Medical Imaging
AI, Inc. Toll-free: 888-988-7465 (PINK) Jodi Regts Perimeter
Medical Imaging AI, Inc. Direct: 469-743-1834 Investors:
investors@perimetermed.com Media: media@perimetermed.com
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025